小児急性非リンパ性白血病 (ANLL) に対するcytosine arabinoside 大量および中等量療法

DOI

書誌事項

タイトル別名
  • High-Dose and Intermediate-Dose Cytosine Arabinoside Therapy for Children with Acute Nonlymphocytic Leukemia
公開日
1987
DOI
  • 10.11412/jjph1987.1.90
公開者
特定非営利活動法人　日本小児血液・がん学会

この論文をさがす

説明

Seven patients with acute nonlymphocytic leukemia (ANLL) including two in bone marrow relapse and five in remission, and one patient with chronic myelocytic leukemia in megakaryoblastic crisis were treated with a high dose of cytosine arabinoside (HD Ara-C) or an intermediate dose of AraC (ID Ara-C). The HD Ara-C therapy consisted of 3-hr intravenous infusion of Ara-C in a dose of 3g/m2 or 1.5g/m2 every 12 hours for 6 days. The ID Ara-C therapy consisted of 2-h intravenous infusion of Ara-C in a dose of 1g/m2 or 1-hr in a dose of 0.5 g/m2. Two patients in bone marrow relapse treated with HD Ara-C achieved complete remission (CR). In both cases, the duration of CR was 4 months. Five patients in remission treated with HD Ara-C or ID Ara-C have remained in CR with a survival duration of 16 to 50 months. Toxicities of HD Ara-C included vomiting, alopecia, conjunctivitis, and marrow suppression. One patient treated with 3g/m2 developed hepatic and splenic microabscesses. Toxicities of ID Ara-C were comparable to conventional treatment. These results indicate that HD Ara-C and ID Ara-C therapy are very useful for children with ANLL.

収録刊行物

キーワード

詳細情報 詳細情報について

  • CRID
    1390282679317618688
  • NII論文ID
    130004345424
  • DOI
    10.11412/jjph1987.1.90
  • ISSN
    18844723
    09138706
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ